Collaborative Efforts to Enhance Opioid Safety
ROXYBOND™, formulated with the innovative SentryBond technology, is designed to offer multiple levels of protection against abuse. Recognizing the importance of safe opioid use, Protega Pharmaceuticals Inc. is partnering with Wellgistics Health, Inc. to enhance pharmacist education and improve patient access to this ground-breaking medication.
About the Collaboration
The collaboration, announced by Wellgistics Health, Inc. (NASDAQ: WGRX), emphasizes the significance of educating pharmacists on the benefits of abuse-deterrent therapies like ROXYBOND™. By leveraging Wellgistics' extensive distribution network that serves over 5,400 independent pharmacies across the nation, the partnership aims to ensure that patients with appropriate prescriptions can access this innovative pain management solution, especially in underserved communities.
The Role of Wellgistics Health
Wellgistics LLC is a key player in this initiative, functioning as a pharmaceutical wholesaler and an authorized distributor by the National Association of Boards of Pharmacy (NABP). Through this partnership, Wellgistics will provide pharmacists with vital resources, enabling them to educate patients about responsible opioid use and ensure compliance with existing regulations.
Impact on Pharmacies and Patient Care
The educational materials designed for pharmacists will cover essential topics, including FDA regulations, best practices for opioid dispensing, and the implications of abuse-deterrent formulations in pain management. This initiative is particularly crucial as more states begin to enact laws that may influence insurance coverage regarding abuse-deterrent medications. By integrating safe dispensing practices into everyday pharmacy operations, the collaboration seeks to safeguard patient health while providing effective pain relief.
Technological Advancements in Pain Management
ROXYBOND™ stands out in the opioid landscape by being the only FDA-approved immediate-release opioid with abuse-deterrent properties. The patented SentryBond technology utilized in ROXYBOND™ seamlessly integrates inactive components with active ingredients to deter misuse, while still offering effective pain management solutions.
FDA Approval and Product Range
The recent approval of a 10 mg strength of ROXYBOND™ has expanded Protega's offerings, which previously included 5 mg, 15 mg, and 30 mg options. This variety allows physicians to tailor opioid pain management more precisely to individual patient needs, aiming to minimize side effects and optimize therapeutic outcomes.
Commitment to Patient Safety
Protega's Chief Commercial Officer, Paul Howe, emphasizes the vital need for independent pharmacists to be equipped with evidence-based education to navigate the complexities of pain management and opioid prescribing. The partnership aligns perfectly with Protega's mission to create a safer opioid market and represents a significant step towards improving care standards across the healthcare landscape.
About Protega Pharmaceuticals Inc.
As a privately held specialty pharmaceutical company, Protega Pharmaceuticals focuses on advancing prescription drug abuse deterrence through innovative technologies. Addressing the public health crisis of opioid abuse, Protega develops immediate-release abuse-deterrent opioid products, with ROXYBOND™ as a leading example of its commitment to safer pain management solutions.
About Wellgistics Health, Inc.
Wellgistics Health, Inc. aims to revolutionize pharmaceutical services and healthcare technology by creating integrated solutions that enhance patient care. Through their innovative business model, Wellgistics addresses access, care coordination, and clinical management in pharmacy operations, supporting patients and healthcare professionals alike.
Frequently Asked Questions
What is ROXYBOND™?
ROXYBOND™ is an immediate-release opioid that combines patented abuse-deterrent technology known as SentryBond to mitigate the risk of misuse.
Why is pharmacist education important in this collaboration?
Educating pharmacists enables them to make informed decisions regarding prescription opioid management, ensuring compliance with regulations and promoting patient safety.
How does the SentryBond technology work?
SentryBond technology integrates inactive ingredients with active medications to deter abuse and manipulation while providing effective pain relief.
What are the benefits of the new dosage options for ROXYBOND™?
The expanded range of dosages allows for more customized pain management strategies, helping healthcare providers optimize treatment for individual patient needs.
How can Wellgistics' distribution network help with patient access?
Wellgistics' extensive network facilitates the distribution of ROXYBOND™ to independent pharmacies, particularly in rural and underserved areas, ensuring that patients have access to necessary medications.
